IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of clinical pathology and
radiology tests to patients in Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. The Group’s core brands include Al Borg, Al Borg
Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan (both in Sudan),
and Biolab KSA (Saudi Arabia). With over 40 years of experience, a long track record for quality and safety has earned the Company
a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 3,000 diagnostics tests. From its
base of 628 branches as of 31 December 2024, IDH served over 8.9 million patients and performed more than 39.2 million tests
in 2024. IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform
for efficient expansion. Beyond organic growth, the Group targets expansion in appealing markets, including acquisitions in the
Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer
trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity (i) whose shares are
admitted to the equity shares (transition) category (previously, the standard listing segment) of the Official List of the UK Financial
Conduct Authority and admitted to trading on the main market for listed securities of the London Stock Exchange (ticker: IDHC)
since May 2015.
Read More on Integrated Diagnostics
